Open prospective randomized controlled study on the effects of SGLT2 inhibitor and bezafibrate on blood glucose control and NAFLD (nonalcoholic fatty liver disease)/START study
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes with nonalcoholic fatty liver disease
- Registration Number
- JPRN-UMIN000027337
- Lead Sponsor
- Saitama Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1.type 1 diabetic patients 2.patients who are being treated for liver disease other than NAFLD 3.Male:serum creatinine higher than 1.2mg/dL Femake:serum creatinine higher than 1.0mg/dL patients 4.Patients who can not be aware of dry mouth 5.SGLT2 inhibitor/Bezafibrate contraindication case 6.Patients with a history of hypersensitivity to SGLT2 inhibitor/Bezafibrate 7.Patients judged to be ineligible by a doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method